Albert Uderzo, the 87-year-old creator of the well-loved French comic series Asterix, has come out of retirement to draw a new cartoon to show solidarity with the victims of the Charlie Hebdo ...

Additionally, Johnson & Johnson is seeking approval for an every-four-week (Q4W) amivantamab dosing regimen. This would be combined with Lazcluze (lazertinib) for first-line treatment of advanced ...

Moreover, the timing of Martinez’s substitution was certainly notable. The 27-year-old came off just a few minutes after Parma had gotten a goal back. And a few minutes before their equalizer.

J&J’s combo of Rybrevant and Lazcluze has racked up an overall survival win versus AZ’s Tagrisso in first-line non-small cell lung cancer.

Pulitzer Prize-winning cartoonist Ann Telnaes resigned from The Washington Post after her cartoon depicting Post owner Jeff Bezos, Mark Zuckerberg, Patrick Soon-Shiong, and Mickey Mouse was ...

Telnaes explained her drawing, stating, "The cartoon that was killed criticizes the billionaire tech and media chief executives who have been doing their best to curry favor with incoming ...

Lung cancer is Europe’s biggest cancer killer, with NSCLC accounting for 85 percent of all lung cancer cases. 2,3 EGFR mutation-positive NSCLC refers to a subtype of lung cancer based on ...

Régis Le Bris said he had no regrets about his substitutions after Sunderland's frustrating draw with Coventry City.

The nation's top political cartoonists debate president-elect's return to the White House ...

Swine-origin influenza viruses show mutations that resist antiviral drugs, posing a pandemic risk and highlighting the urgent need for ongoing surveillance and updated treatment strategies. Study ...

West Ham manager Julen Lopetegui has opened up on his decision to substitute Mohammed Kudus at halftime during the 1-1 draw against Brentford, clarifying that it was a tactical move rather than ...

References 1. FDA approves amivantamab-vmjw with carboplatin and pemetrexed for non–small cell lung cancer with EGFR exon 19 deletions or L858R mutations. FDA. News release. September 19, 2024.